



Dedicated To Life

November 12, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East)
Mumbai-400051

Code: Zyduslife

Re.: **Newspaper publication**

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / half year ended on September 30, 2022 in Financial Express on November 12, 2022.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above



Place: New Delhi

Narayan Saboo (Director)
DIN: 00749265

Date: 11/11/2022

NARAYAN SABOO
DIRECTOR

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduslife.com

CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30/09/2022

Sr. No.	Particulars	₹ In Million					
		3 Months ended 30/09/2022 (Unaudited)	Preceding 3 Months ended 30/06/2022 (Unaudited)	Corresponding 3 Months ended 30/09/2021 in the previous year (Unaudited)	Year to date figures for the current period ended 30/09/2022 (Unaudited)	Year to date figures for the previous period ended 30/09/2021 (Unaudited)	Previous year ended 31/03/2022 (Audited)
1	Total income from operations	41,347	40,727	37,598	82,074	77,616	1,52,652
2	Net Profit for the period before exceptional items and tax	6,428	6,839	7,454	13,267	15,483	27,254
3	Net Profit for the period after exceptional items but before tax	6,428	6,810	8,581	13,238	16,610	28,381
4	Net Profit for the period from continuing operations	5,170	5,266	7,251	10,436	13,223	22,416
5	Profit/ (Loss) after tax from discontinued operations	55	(83)	22,772	(28)	22,672	22,457
6	Net Profit for the period after tax and Non-Controlling Interest	5,225	5,183	30,023	10,408	35,895	44,873
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	4,357	3,608	30,139	7,965	35,607	43,832
8	Paid-up equity share capital (Face value ₹ 1/-)	1,012	1,024	1,024	1,012	1,024	1,024
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						1,68,972
10	Earnings per share for continuing operations (not annualised for the quarter and half year)						
a	Basic (₹)	5.10	5.14	7.08	10.24	12.92	21.90
b	Diluted (₹)	5.10	5.14	7.08	10.24	12.92	21.90
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and half year)						
a	Basic (₹)	5.15	5.06	29.33	10.21	35.06	43.83
b	Diluted (₹)	5.15	5.06	29.33	10.21	35.06	43.83

Note:

[1] The above is an extract of the detailed format of Quarterly/Half yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/Half yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, November 11, 2022



Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30/09/2022

Sr. No.	Particulars	₹ in Million					
		3 Months ended 30/09/2022	Preceding 3 Months ended 30/06/2022	Corresponding 3 Months ended 30/09/2021 in the previous year	Year to date figures for the current period ended 30/09/2022	Year to date figures for the previous period ended 30/09/2021	Previous year ended 31/03/2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	41,347	40,727	37,598	82,074	77,616	1,52,652
2	Net Profit for the period before exceptional items and tax	6,428	6,839	7,454	13,267	15,483	27,254
3	Net Profit for the period after exceptional items but before tax	6,428	6,810	8,581	13,238	16,610	28,381
4	Net Profit for the period from continuing operations	5,170	5,266	7,251	10,436	13,223	22,416
5	Profit/ (Loss) after tax from discontinued operations	55	(83)	22,772	(28)	22,672	22,457
6	Net Profit for the period after tax and Non-Controlling Interest	5,225	5,183	30,023	10,408	35,895	44,873
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	4,357	3,608	30,139	7,965	35,607	43,832
8	Paid-up equity share capital (Face value ₹ 1/-)	1,012	1,024	1,024	1,012	1,024	1,024
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						1,68,972
10	Earnings per share for continuing operations (not annualised for the quarter and half year)						
a	Basic (₹)	5.10	5.14	7.08	10.24	12.92	21.90
b	Diluted (₹)	5.10	5.14	7.08	10.24	12.92	21.90
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and half year)						
a	Basic (₹)	5.15	5.06	29.33	10.21	35.06	43.83
b	Diluted (₹)	5.15	5.06	29.33	10.21	35.06	43.83

Note:

[1] The above is an extract of the detailed format of Quarterly/Half yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/Half yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, November 11, 2022